Key Points
- Insider sale: PTC Therapeutics insider Eric Pauwels sold 20,508 shares on Dec. 19 at an average price of $77.26 for $1,584,448, leaving him with 70,373 shares — a 22.57% reduction in his position.
- Clustered disposals: Pauwels sold a total of 64,000 shares from Dec. 17–19 (40,290 on Dec. 17 and 3,202 on Dec. 18), generating roughly $4.86 million in proceeds across the three trades.
- Company context: PTCT trades near $77.70 (52-week range $35.95–$87.50) with a $6.24B market cap; the stock has a consensus "Hold" rating with a $76 target after a recent quarter that beat EPS and revenue estimates.
PTC Therapeutics, Inc. (NASDAQ:PTCT - Get Free Report) insider Eric Pauwels sold 20,508 shares of the stock in a transaction on Friday, December 19th. The shares were sold at an average price of $77.26, for a total value of $1,584,448.08. Following the completion of the transaction, the insider owned 70,373 shares of the company's stock, valued at $5,437,017.98. This trade represents a 22.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.
Eric Pauwels also recently made the following trade(s):
- On Wednesday, December 17th, Eric Pauwels sold 40,290 shares of PTC Therapeutics stock. The shares were sold at an average price of $75.43, for a total transaction of $3,039,074.70.
- On Thursday, December 18th, Eric Pauwels sold 3,202 shares of PTC Therapeutics stock. The stock was sold at an average price of $75.06, for a total value of $240,342.12.
PTC Therapeutics Price Performance
NASDAQ PTCT opened at $77.70 on Wednesday. The company has a 50 day simple moving average of $74.05 and a 200-day simple moving average of $60.48. PTC Therapeutics, Inc. has a 52-week low of $35.95 and a 52-week high of $87.50. The firm has a market capitalization of $6.24 billion, a price-to-earnings ratio of 9.08, a price-to-earnings-growth ratio of 0.28 and a beta of 0.47.
PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating the consensus estimate of ($1.19) by $1.39. PTC Therapeutics had a net margin of 42.25% and a negative return on equity of 194.11%. The business had revenue of $211.01 million for the quarter, compared to analysts' expectations of $177.42 million. During the same period in the previous year, the company posted ($1.39) EPS. PTC Therapeutics's revenue was up 7.2% on a year-over-year basis. On average, analysts predict that PTC Therapeutics, Inc. will post -4.52 EPS for the current year.
Institutional Investors Weigh In On PTC Therapeutics
Several hedge funds and other institutional investors have recently added to or reduced their stakes in PTCT. Wellington Management Group LLP boosted its position in PTC Therapeutics by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 4,918,619 shares of the biopharmaceutical company's stock valued at $301,856,000 after buying an additional 224,481 shares during the last quarter. State Street Corp lifted its stake in shares of PTC Therapeutics by 22.1% during the second quarter. State Street Corp now owns 2,996,454 shares of the biopharmaceutical company's stock valued at $146,347,000 after acquiring an additional 541,558 shares during the period. Geode Capital Management LLC boosted its holdings in PTC Therapeutics by 3.2% in the second quarter. Geode Capital Management LLC now owns 1,934,593 shares of the biopharmaceutical company's stock valued at $94,497,000 after acquiring an additional 60,707 shares during the last quarter. Jefferies Financial Group Inc. acquired a new stake in PTC Therapeutics in the third quarter worth about $97,252,000. Finally, Driehaus Capital Management LLC raised its holdings in PTC Therapeutics by 45.3% during the 1st quarter. Driehaus Capital Management LLC now owns 1,512,645 shares of the biopharmaceutical company's stock worth $77,084,000 after purchasing an additional 471,586 shares during the last quarter.
Analyst Upgrades and Downgrades
Several brokerages recently commented on PTCT. Weiss Ratings reiterated a "hold (c)" rating on shares of PTC Therapeutics in a report on Monday. TD Cowen increased their target price on PTC Therapeutics from $50.00 to $63.00 and gave the company a "hold" rating in a research note on Wednesday, November 5th. Wall Street Zen cut shares of PTC Therapeutics from a "buy" rating to a "hold" rating in a research note on Saturday, December 6th. Barclays boosted their price target on PTC Therapeutics from $46.00 to $68.00 and gave the company an "equal weight" rating in a research note on Wednesday, November 5th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $118.00 price objective on shares of PTC Therapeutics in a research report on Wednesday, September 3rd. Nine equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $76.00.
View Our Latest Stock Analysis on PTC Therapeutics
About PTC Therapeutics
(
Get Free Report)
PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.
Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
